Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: Preliminary data

被引：0

作者：

Delaunay, C ^{[1
]}

Farrenq, V ^{[1
]}

Marini-Portugal, A ^{[1
]}

Cohen, JD ^{[1
]}

Chevalier, X ^{[1
]}

Claudepierre, P ^{[1
]}

机构：

[1] Henri Mondor Teaching Hosp, Dept Rheumatol, Creteil, France

来源：

JOURNAL OF RHEUMATOLOGY | 2005年 / 32卷 / 11期

关键词：

spondyloarthropathy; psoriatic arthritis; etanercept; infliximab; switch treatment; anti-tumor necrosis factor;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To report early experience of switching anti-tumor necrosis factor-alpha (TNF-alpha) therapy from infliximab to etanercept in patients with spondyloarthropathy (SpA) and psoriatic arthritis (PsA). Methods. Thirteen patients with various SpA (7 with ankylosing spondylitis and 6 with undifferentiated SpA) and 2 patients with PsA were receiving infliximab. Because they were experiencing inadequate response or adverse events, therapy was changed to etanercept. Patients were evaluated for response to the change in anti-TNF-alpha therapy at baseline, after 3 months, and then every 6 months. Results. During the mean 10-month followup after the change in therapy, 9 of 13 patients with SpA and both patients with PsA responded to etanercept and none experienced intolerance to this agent. Conclusion. These data suggest that switching between anti-TNF-alpha drugs may be useful for patients with SpA who are unresponsive or intolerant to a first anti-TNF-alpha agent.

引用

页码：2183 / 2185

页数：3

共 50 条

[1] Predictors for terminating therapy of etanercept and infliximab in psoriatic arthritis patients
Kristensen, L. E.
Nilsson, J.
Jacobsson, L. T. H.
Saxne, T.
Compagno, M.
Geborek, P.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 222 - 222
[2] Psoriatic arthritis patients doing better on infliximab than etanercept
Smith, N.
Gadsby, K.
Deighton, C.
[J]. RHEUMATOLOGY, 2007, 46 (04): : 721 - 722
[3] Predictors for terminating therapy of etanercept and infliximab in psoriatic arthritis patients.
Kristensen, Lars Erik
Geborek, Pierre
Nilsson, Jan- ke
Saxne, Tore
Compagno, Michele
Jacobsson, Lennart
[J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S721 - S722
[4] Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis
Dafna D Gladman
[J]. Nature Clinical Practice Rheumatology, 2008, 4 : 510 - 511
[5] The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis
Vergel, Y. Bravo
Hawkins, N. S.
Claxton, K.
Asseburg, C.
Palmer, S.
Woolacott, N.
Bruce, I. N.
Sculpher, M. J.
[J]. RHEUMATOLOGY, 2007, 46 (11) : 1729 - 1735
[6] Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis
Gladman, Dafna D.
[J]. NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2008, 4 (10): : 510 - 511
[7] Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review
Woolacott, N. F.
Khadjesari, Z. C. S.
Bruce, I. N.
Riemsma, R. P.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2006, 24 (05) : 587 - 593
[8] Comparison of healthcare costs in patients with psoriatic arthritis who received etanercept, etanercept plus methotrexate, infliximab, or infliximab plus MTX
Dabbous, O.
Rahman, M.
Meissner, B.
Thompson, H.
Tang, B.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 258 - 258
[9] EXPERIENCE IN THE SWITCH FROM INFLIXIMAB TO ETANERCEPT, OR VICE VERSA IN RHEUMATOID ARTHRITIS PATIENTS
Estefania, M.
Alba, E.
Luciana, G.
Ana, U.
Carlos, T.
Sara, M.
[J]. RHEUMATOLOGY, 2002, 41 : 93 - 94
[10] Efficacy of etanercept in psoriatic patients previously treated with infliximab
Pitarch, Gerard
Luis Sanchez-Carazo, Jose
Mahiques, Laura
Oliver, Vicente
[J]. DERMATOLOGY, 2008, 216 (04) : 312 - 316

← 1 2 3 4 5 →